Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

被引:243
作者
Tsao, Ming-Sound [1 ,2 ]
Marguet, Sophie [5 ]
Le Teuff, Gwenael [5 ]
Lantuejoul, Sylvie [6 ]
Shepherd, Frances A. [1 ,2 ]
Seymour, Lesley [3 ,4 ]
Kratzke, Robert [8 ]
Graziano, Stephen L. [9 ]
Popper, Helmut H. [10 ]
Rosell, Rafael [11 ]
Douillard, Jean-Yves [7 ]
Le-Chevalier, Thierry [5 ]
Pignon, Jean-Pierre [5 ]
Soria, Jean-Charles [5 ]
Brambilla, Elisabeth M. [6 ]
机构
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] NCIC Clin Trials Grp, Kingston, ON, Canada
[4] Queens Univ, Kingston, ON, Canada
[5] Gustave Roussy, Villejuif, France
[6] Univ Grenoble 1, CHU Grenoble, Inst Albert Bonniot, Inserm U823, Grenoble, France
[7] Ctr Rene Gauducheau, Nantes, France
[8] Univ Minnesota, Minneapolis, MN USA
[9] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[10] Univ Med Sch Graz, Inst Pathol, Graz, Austria
[11] Catalan Inst Oncol, Barcelona, Spain
基金
欧盟第七框架计划;
关键词
VINORELBINE PLUS CISPLATIN; IASLC/ATS/ERS CLASSIFICATION; INTERNATIONAL-ASSOCIATION; PULMONARY ADENOCARCINOMAS; PROGNOSTIC VALUE; POOLED ANALYSIS; CANCER; SURVIVAL; DISEASE; TRIALS;
D O I
10.1200/JCO.2014.58.8335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and WHO is based on the predominant histologic patternlepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or solid (SOL)present in the tumor. This classification has not been tested in multi-institutional cohorts or clinical trials or tested for its predictive value regarding survival from adjuvant chemotherapy (ACT). Patients and Methods Of 1,766 patients in the IALT, JBR.10, CALGB 9633 (Alliance), and ANITA ACT trials included in the LACE-Bio study, 725 had adenocarcinoma. Histologies were reclassified according to the new classification and then collapsed into three groups (LEP, ACN/PAP, and MIP/SOL). Primary end point was overall survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS). Hazard ratios (HRs) and 95% CIs were estimated through multivariable Cox models stratified by trial. Prognostic value was estimated in the observation arm and predictive value by a treatment effect interaction with histologic subgroups. Significance level was set at .01 for pooled analysis. Results A total of 575 patients were included in this analysis. OS was not prognostically different between histologic subgroups, but univariable DFS and SDFS were worse for MIP/SOL compared with LEP or ACN/PAP subgroup (P < .01); this remained marginally significant after adjustment. MIP/SOL patients (but not ACN/PAP) derived DFS and SDFS but not OS benefit from ACT (OS: HR, 0.71; 95% CI, 0.51 to 0.99; interaction P = .18; DFS: HR, 0.60; 95% CI, 0.44 to 0.82; interaction P = < .01; and SDFS: HR, 0.59; 95% CI, 0.42 to 0.81; interaction P = <.01). Conclusion The new lung adenocarcinoma classification based on predominant histologic pattern was not predictive for ACT benefit for OS, but it seems predictive for disease-specific outcomes.
引用
收藏
页码:3439 / +
页数:10
相关论文
共 31 条
[21]   The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations [J].
Tsuta, Koji ;
Kawago, Mitsumasa ;
Inoue, Eisuke ;
Yoshida, Akihiko ;
Takahashi, Fumiaki ;
Sakurai, Hiroyuki ;
Watanabe, Shun-ichi ;
Takeuchi, Masahiro ;
Furuta, Koh ;
Asamura, Hisao ;
Tsuda, Hitoshi .
LUNG CANCER, 2013, 81 (03) :371-376
[22]   Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas [J].
Warth, Arne ;
Stenzinger, Albrecht ;
von Bruenneck, Ann-Christin ;
Goeppert, Benjamin ;
Cortis, Judith ;
Petersen, Iver ;
Hoffmann, Hans ;
Schnabel, Philipp A. ;
Weichert, Wilko .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (05) :1221-1227
[23]   Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification [J].
Warth, Arne ;
Cortis, Judith ;
Fink, Ludger ;
Fisseler-Eckhoff, Annette ;
Geddert, Helene ;
Hager, Thomas ;
Junker, Klaus ;
Kayser, Gian ;
Kitz, Julia ;
Laenger, Florian ;
Morresi-Hauf, Alicia ;
Ott, German ;
Petersen, Iver ;
Stenzinger, Albrecht ;
Soltermann, Alex ;
Ting, Saskia ;
Tischler, Verena ;
Vollmer, Ekkehard ;
Schnabel, Philipp A. ;
Weichert, Wilko .
VIRCHOWS ARCHIV, 2012, 461 (02) :185-193
[24]   The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival [J].
Warth, Arne ;
Muley, Thomas ;
Meister, Michael ;
Stenzinger, Albrecht ;
Thomas, Michael ;
Schirmacher, Peter ;
Schnabel, Philipp A. ;
Budczies, Jan ;
Hoffmann, Hans ;
Weichert, Wilko .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) :1438-1446
[25]   Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer [J].
Winton, T ;
Livingston, R ;
Johnson, D ;
Rigas, J ;
Johnston, M ;
Butts, C ;
Cormier, Y ;
Goss, G ;
Inculet, R ;
Vallieres, E ;
Fry, W ;
Bethune, D ;
Ayoub, J ;
Ding, K ;
Seymour, L ;
Graham, B ;
Tsao, MS ;
Gandara, D ;
Kesler, K ;
Demmy, T ;
Shepherd, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2589-2597
[26]   Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases [J].
Woo, Tetsukan ;
Okudela, Koji ;
Mitsui, Hideaki ;
Tajiri, Michihiko ;
Yamamoto, Taketsugu ;
Rino, Yasushi ;
Ohashi, Kenichi ;
Masuda, Munetaka .
PATHOLOGY INTERNATIONAL, 2012, 62 (12) :785-791
[27]   New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma [J].
Yanagawa, Naoki ;
Shiono, Satoshi ;
Abiko, Masami ;
Ogata, Shin-ya ;
Sato, Toru ;
Tamura, Gen .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (05) :612-618
[28]   Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations Analysis of 440 Japanese Patients [J].
Yoshizawa, Akihiko ;
Sumiyoshi, Shinji ;
Sonobe, Makoto ;
Kobayashi, Masashi ;
Fujimoto, Masakazu ;
Kawakami, Fumi ;
Tsuruyama, Tatsuaki ;
Travis, William D. ;
Date, Hiroshi ;
Haga, Hironori .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) :52-61
[29]   Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases [J].
Yoshizawa, Akihiko ;
Motoi, Noriko ;
Riely, Gregory J. ;
Sima, Cami S. ;
Gerald, William L. ;
Kris, Mark G. ;
Park, Bernard J. ;
Rusch, Valerie W. ;
Travis, William D. .
MODERN PATHOLOGY, 2011, 24 (05) :653-664
[30]   Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification [J].
Zhang, Jie ;
Wu, Jie ;
Tan, Qiang ;
Zhu, Lei ;
Gao, Wen .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (09) :1196-1202